Investor Presentation First Nine Months of 2022
6
Investor presentation First nine months of 2022
Diabetes value market leadership increased by 1.7%-points to
31.6%
Novo Nordisk global diabetes value market shares
Diabetes value market leadership expansion
driven by the GLP-1 franchise
60%
-Diabetes
-GLP-1
-Insulin
55.7%
49.9%
50%
46.8%
52.1%
44.6%
44.3%
44.0%
44.2%
40%
31.6%
28.4%
29.2%
29.9%
30%
0% T
2019
2020
2021
2022
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Source: IQVIA MAT, Aug 2022 (Spot rate)
Note: Sales growth rates are at CER
Novo NordiskⓇ
Diabetes care sales grew by 14% with global value market share
increase driven by GLP-1 market share gains in both IO and NAO
Insulin value market share has slightly increased from 44.0% to
44.2% in the last 12 months
GLP-1 value market share has increased by 3.6%-points in the last
12 months, driven by:
•
•
OzempicⓇ launches and uptake in 75 countries
RybelsusⓇ uptake in North America Operations and
launches in International Operations
Global GLP-1 volume growth of ~44%
.
GLP-1 is only 4% of total diabetes prescriptionsView entire presentation